Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 170

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

Open access
Harrington, K J, Billingham, L J, Brunner, T B, Burnet, N G, Chan, C S, Hoskin, P, Mackay, R I, Maughan, T S, Macdougall, J, McKenna, W G, Nutting, C M, Oliver, A, Plummer, R, Stratford, I J, Illidge, T, NCRI Clinical and Translational Radiotherapy Research Working Group · 2011 · British Journal of Cancer

Abstract

There is a growing appreciation of the potential value of combining novel molecularly-targeted drugs with radiotherapy or chemoradiotherapy. Such approaches have the potential to improve locoregional disease control and cure rates across a diverse range of tumour types. In this report, we outline a rational framework for developing novel drug–radiation combinations. In doing so, we make recommendations regarding the core preclinical data sets that are required to serve as justification for studies in humans and describe potential clinical trial designs that may be adopted by investigators. Radiotherapy (RT) has a pivotal role in the management of many tumours, such that ∼ 50% of cancer patients will receive RT during the course of their illnesses and 40% of those cured of cancer will have received RT as part of their treatment ( http://info.cancerresearchuk.org/ ). Indications for prescribing RT include (i) definitive, curative (radical) treatment; (ii) adjuvant therapy following surgery in an attempt to eradicate microscopic (or rarely macroscopic) residual disease; and (iii) as palliative treatment to ameliorate cancer-related symptoms. In the majority of situations, RT is a highly localised treatment that targets defined volumes of tissue that are known (or suspected) to contain cancer cells. Wide-field hemi-body ( Bashir et al, 2008 ) or total body ( Adkins and DiPersio, 2008 ) irradiation techniques are used rarely in very specific indications, such as metastatic bone disease or ‘conditioning’ before transplantation in haematological malignancies, respectively. In addition, the latest developments in stereotactic body RT (SBRT) techniques have also resulted in protocols that aim to treat oligometastatic disease spread through an organ (or more than one organ) with very precisely delivered RT fields and ablative doses ( Benedict et al, 2010 ). This use of SBRT will certainly expand in the next decade and should be an active area for clinical trials. In recent years, significant improvements have occurred in our technical ability to deliver RT to the target volume (tumour and/or locoregional lymph nodes), while limiting its delivery to critical normal structures. Techniques such as three-dimensional conformal RT, intensity-modulated RT and image-guided RT offer the prospect of significant benefits, both in terms of dose escalation within the tumour and dose sparing in normal organs ( Bhide and Nutting, 2010 ; Staffurth, 2010 ). Clinical studies to test each of these strategies are ongoing in various tumour types; however, the expectation is that gains in tumour control probability may be clinically significant but relatively modest (<10%). In addition, in the near future it is likely that an increasing number of centres will have the capacity to deliver proton and heavy ion therapy. This technology offers highly conformal treatment and may allow clinicians to achieve dose escalation in the tumour while simultaneously sparing normal structures. Systemic cytotoxic chemotherapy is increasingly combined with RT in an attempt to increase tumour control as well as targeting micrometastatic disease outside the radiation fields early in the treatment process ( Bentzen et al, 2007 ). A range of cytotoxic agents has been tested in early trials, but most recent studies have focussed on platins, anti-metabolites (5-FU, gemcitabine) and taxanes. The data set derived from a meta-analysis in squamous cell cancer of the head and neck is particularly strong and definitively shows that the greatest benefit from combining chemotherapy with RT accrues when the agents are administered concomitantly ( Pignon et al, 2000 ). Furthermore, the most clinically active drug is a DNA-damaging agent, cisplatin. These findings suggest that the temporal relationship between the two modalities and the mode of action of the cytotoxic drug are important components of the interaction and have led to cisplatin being used as a ‘radiosensitiser’ in a range of indications. In the case of radical and adjuvant RT, a number of studies have confirmed benefit when systemically administered cytotoxic chemotherapy is combined with RT (chemo-RT) ( Pignon et al, 2000 ; Green et al, 2001 ; Urschel and Vasan, 2003 ; Bernier et al, 2004 , 2005 ; Cooper et al, 2004 ; Lordick and Siewert, 2005 ; Auperin et al, 2006 ; Stupp et al, 2009 ). These studies across a range of tumour types (head and neck, lung, uterine cervical, gastric, oesophageal cancers and glioblastoma multiforme) have shown improved locoregional control, progression-free survival and, in some circumstances, overall survival. There is, as yet, little evidence that this systemic therapy has a strong influence on the rates of distant relapse. It is likely that this trend will continue and chemo-RT may become a standard of care in a wider range of cancers. In the context of palliative RT, there are currently no clinical scenarios in which combined drug and radiation therapy is the standard of care

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/bjc.2011.240

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Cited by

See all 170

Metadata

Authors
Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., Mackay, R. I., Maughan, T. S., Macdougall, J., McKenna, W. G., Nutting, C. M., Oliver, A., Plummer, R., Stratford, I. J., Illidge, T., & NCRI Clinical and Translational Radiotherapy Research Working Group
Venue
British Journal of Cancer
Published
2011-07-19
Volume
105
Issue
5
Pages
628-639
ISSN
  • 0007-0920 (ISSN-L)
  • 1532-1827
OpenAlex
W2026576427
Cited by
170
References
4
FWCI
6.68
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. https://app.cochat.ai/papers/10.1038/bjc.2011.240
The paper
Harrington, K. J., Billingham, L. J., Brunner, T. B., Burnet, N. G., Chan, C. S., Hoskin, P., Mackay, R. I., Maughan, T. S., Macdougall, J., McKenna, W. G., Nutting, C. M., Oliver, A., Plummer, R., Stratford, I. J., Illidge, T., & NCRI Clinical and Translational Radiotherapy Research Working Group. (2011). Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers. British Journal of Cancer. https://doi.org/10.1038/bjc.2011.240

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.